Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$93.75NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/16/19

Today's Change+0.26(0.28%)
Bid (Size)$93.75 (234)
Ask (Size)$95.20 (10)
Day Low / High$92.42 - 93.98
Volume436.9 K

View Biotechnology IndustryPeer Comparison as of 10/16/2019


Neurocrine Biosciences Inc ( NASDAQ )

Price: $93.75
Change: +0.26 (0.28%)
Volume: 436.9 K
4:00PM ET 10/16/2019

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $57.62
Change: -3.84 (6.25%)
Volume: 2.2 M
4:00PM ET 10/16/2019

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $81.67
Change: +0.82 (1.01%)
Volume: 793.2 K
3:59PM ET 10/16/2019

Bio-Techne Corp ( NASDAQ )

Price: $202.03
Change: +1.39 (0.69%)
Volume: 104.2 K
4:00PM ET 10/16/2019

Sarepta Therapeutics Inc ( NASDAQ )

Price: $86.73
Change: -1.32 (1.50%)
Volume: 782.1 K
4:00PM ET 10/16/2019

Read more news Recent News

Neurocrine Says Study Shows Potential of Ingrezza in Reducing Involuntary Movements in Tardive Dyskinesia
4:01AM ET 10/07/2019 MT Newswires

Neurocrine Biosciences (NBIX), developer of treatments for neurological and endocrine based diseases, said late Friday that data from several long-term...

Neurocrine Biosciences Presenting More Ingrezza Data at Industry Conference This Week
4:17PM ET 10/01/2019 MT Newswires

Neurocrine Biosciences (NBIX) was steady in late Tuesday trading after saying it will present new data analysis supporting the long-term effects of its...

Research Alert: CFRA Keeps Hold Opinion On Shares Of Neurocrine Biosciences, Inc.
4:20PM ET 8/15/2019 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

--Analyst Actions: RBC Initiates Neurocrine Biosciences at Outperform With $118-a-Share Price Target
8:14AM ET 8/07/2019 MT Newswires

Price: 95.00, Change: +0.05, Percent Change: +0.05 ...

View all Commentary and Analysis

Three Q4'19 Catalysts For Axovant
8:54AM ET 9/17/2019 Seeking Alpha

Neurocrine Biosciences (NBIX) Presents At Baird Global Healthcare Conference - Slideshow
11:52AM ET 9/11/2019 Seeking Alpha

Neurocrine Keeps Rolling (Q3 Update)
8:54AM ET 8/21/2019 Seeking Alpha

Neurocrine Executing Very Well With Its Lead Commercial Compound
7:49AM ET 8/01/2019 Seeking Alpha

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Number of Employees585
Recent SEC Filing10/16/20194
Chief Executive Officer & DirectorKevin Charles Gorman
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis
Vice President-Information Technology & OperationsBill Wilson

Company Highlights

Price Open$92.89
Previous Close$93.49
52 Week Range$64.72 - 116.48
Market Capitalization$8.6 B
Shares Outstanding91.6 M
SectorHealth Technology
Next Earnings Announcement11/04/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings694.85
Earnings per Share$0.87
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin2.98%
Return on Equity3.97%

Analyst Ratings as of 08/06/2019

Consensus RecommendationConsensus Icon
Powered by Factset